Medgenics Inc Block Listing Interim Review (1227X)
07 Janvier 2014 - 7:00PM
UK Regulatory
TIDMMEDG TIDMMEDU
RNS Number : 1227X
Medgenics Inc
07 January 2014
Press Release 7 January 2014
Medgenics, Inc.
(the "Company")
Block Listing Interim Review
1. Name of company:
Medgenics, Inc.
2. Name of scheme:
Warrants, Options and Restricted Shares under the Company's
Share Incentive Schemes
3. Period of return:
From To
------------ ---------------
6 July 2013 5 January 2014
------------ ---------------
4. Number and class of securities not issued under the scheme at
the beginning of the period:
(i) MEDG TIDM - 715,315 common shares of par value of US$0.0001
each ("Common Shares") Regulation S restrictions, ISIN USU582411158
("Reg S"); and
(ii) MEDU TIDM - 545,581 Common Shares ISIN US58436Q2030
5. Number of securities issued under scheme during period:
(i) MEDG TIDM (Reg. S) - 56,000 Common Shares following
Restricted Shares issued by the Company
(ii) MEDU TIDM - 15,999 Common Shares following the due exercise
of Warrants issued by the Company
6. Balance under scheme of securities not yet issued at end of
period:
(i) MEDG TIDM (Reg. S) - 659,315 Common Shares
(ii) MEDU TIDM - 529,582 Common Shares
7. Number and class of securities originally admitted and the
date of admission:
(i) MEDG TIDM (Reg. S) - 963,119 Common Shares (6 July 2011)
(ii) MEDU TIDM - 963,119 Common Shares (6 July 2011).
Following the above issues during the period the total number of
Common Shares in issue is 18,553,307. The percentage of shares not
in public hands is 18.3 per cent.
- Ends -
For further information, contact:
Medgenics, Inc.
John Leaman, CFO
john.leaman@medgenics.com
Abchurch Communications Phone: +44 207 398 7719
Harriet Rae
Joanne Shears
Jamie Hooper
jamie.hooper@abchurch-group.com
Oriel Securities (NOMAD & Broker) Phone: +44 207 710 7617
Jonathan Senior
Giles Balleny
About Medgenics
Medgenics is developing and commercializing Biopump(TM), a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own tissue for the treatment of a range of chronic diseases
including anemia and hepatitis, among others. For more information,
please visit www.medgenics.com.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend, "
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
-ENDS-
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRUBVNRSBAARAR
Medgenics (LSE:MEDU)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Medgenics (LSE:MEDU)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024